- In January 2025, Bachem Holding AG, a leading peptide manufacturer, announced the expansion of its manufacturing capacity in Switzerland, aiming to meet the growing global demand for peptide APIs. The new facility will include advanced solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS) capabilities, enabling the production of highly complex peptides with improved scalability and efficiency. The investment also focuses on integrating cutting-edge purification technologies to ensure high-quality peptide APIs for pharmaceutical applications
- In October 2024, Lonza Group AG announced the completion of its peptide manufacturing facility expansion in Visp, Switzerland. The facility now features state-of-the-art production technologies, including continuous flow manufacturing, which significantly reduces production time and cost. This strategic move strengthens Lonza's position as a key player in the global peptide API market, supporting the growing demand for personalized medicine and biologics
- In September 2024, Polypeptide Group unveiled a new, fully automated peptide synthesis platform at its Malmö, Sweden, facility. This platform leverages advanced automation and AI-driven process control to enhance efficiency, reduce batch-to-batch variability, and optimize production costs. The company also announced plans to invest in downstream processing capabilities to improve peptide purification and scalability
- In September 2024, AmbioPharm Inc. launched a new state-of-the-art manufacturing facility in South Carolina, U.S., focused on the production of high-purity peptide APIs for clinical and commercial applications. The facility includes cutting-edge SPPS and purification technologies, designed to support the increasing demand for complex peptide therapeutics in the global market
- In August 2024, WuXi AppTec announced the expansion of its peptide manufacturing capabilities at its Changzhou, China, site. The expansion includes the addition of large-scale reactors, advanced analytical testing facilities, and a fully integrated quality control system, enhancing its ability to deliver high-quality peptide APIs for pharmaceutical clients worldwide
